Neuropsychiatric and Psychosocial Issues of Patients With Hepatitis C Infection: A Selective Literature Review

Authors Information
Article Notes and Dates
To Cite : Modabbernia A, Poustchi H, Malekzadeh R. Neuropsychiatric and Psychosocial Issues of Patients With Hepatitis C Infection: A Selective Literature Review, Hepat Mon. 2013 ;13(1):e8340. doi: 10.5812/hepatmon.8340.
Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnotes
References
  • 1. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007; 46(3): 420-31[DOI][PubMed]
  • 2. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4): 1335-74[DOI][PubMed]
  • 3. Crone C, Gabriel GM. Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. J Psychiatr Pract. 2003; 9(2): 93-110[PubMed]
  • 4. Forton DM, Thomas HC, Taylor-Robinson SD. Quality of life and cognitive function in chronic hepatitis C - what to measure? J Hepatol. 2003; 39(2): 272-4[PubMed]
  • 5. Foster GR. Quality of life considerations for patients with chronic hepatitis C. J Viral Hepat. 2009; 16(9): 605-11[DOI][PubMed]
  • 6. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005; 41(4): 790-800[DOI][PubMed]
  • 7. Miller ER, McNally S, Wallace J, Schlichthorst M. The ongoing impacts of hepatitis c - a systematic narrative review of the literature. BMC Public Health. 2012; 12(1): 672[DOI][PubMed]
  • 8. Amodio P, Salari L, Montagnese S, Schiff S, Neri D, Bianco T, et al. Hepatitis C virus infection and health-related quality of life. World J Gastroenterol. 2012; 18(19): 2295-9[DOI][PubMed]
  • 9. Ashrafi M, Modabbernia A, Dalir M, Taslimi S, Karami M, Ostovaneh MR, et al. Predictors of mental and physical health in non-cirrhotic patients with viral hepatitis: A case control study. J Psychosom Res. 2012; 73(3): 218-24[DOI][PubMed]
  • 10. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998; 27(1): 209-12[DOI][PubMed]
  • 11. Modabbernia A, Ashrafi M, Keyvani H, Taslimi S, Poorkaveh A, Merat S, et al. Brain-derived neurotrophic factor predicts physical health in untreated patients with hepatitis C. Biol Psychiatry. 2011; 70(5)-2[DOI][PubMed]
  • 12. Bondini S, Kallman J, Dan A, Younoszai Z, Ramsey L, Nader F, et al. Health-related quality of life in patients with chronic hepatitis B. Liver Int. 2007; 27(8): 1119-25[DOI][PubMed]
  • 13. Dan AA, Kallman JB, Wheeler A, Younoszai Z, Collantes R, Bondini S, et al. Health-related quality of life in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2007; 26(6): 815-20[DOI][PubMed]
  • 14. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD. Evidence for a cerebral effect of the hepatitis C virus. Lancet. 2001; 358(9275): 38-9[DOI][PubMed]
  • 15. Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 2002; 35(2): 433-9[DOI][PubMed]
  • 16. Forton DM, Allsop JM, Cox IJ, Hamilton G, Wesnes K, Thomas HC, et al. A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. AIDS. 2005; 19 Suppl 3-63[PubMed]
  • 17. Forton DM, Taylor-Robinson SD, Thomas HC. Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat. 2003; 10(2): 81-6[PubMed]
  • 18. Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology. 2002; 35(2): 440-6[DOI][PubMed]
  • 19. Kramer L, Hofer H, Bauer E, Funk G, Formann E, Steindl-Munda P, et al. Relative impact of fatigue and subclinical cognitive brain dysfunction on health-related quality of life in chronic hepatitis C infection. AIDS. 2005; 19 Suppl 3-92[PubMed]
  • 20. Bownik H, Saab S. The effects of hepatitis C recurrence on health-related quality of life in liver transplant recipients. Liver Int. 2010; 30(1): 19-30[DOI][PubMed]
  • 21. Poynard T, Cacoub P, Ratziu V, Myers RP, Dezailles MH, Mercadier A, et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat. 2002; 9(4): 295-303[PubMed]
  • 22. Seaman K, Paterson BL, Vallis M, Hirsch G, Peltekian KM. Future directions for investigation of fatigue in chronic hepatitis C viral infection. Chronic Illn. 2009; 5(2): 115-28[DOI][PubMed]
  • 23. Racciatti D, Gorgoretti V, Sepede G, Gambi F, Pizzigallo E. An Italian study on health-related quality of life and fatigue in patients with chronic fatigue syndrome and patients with chronic HCV virus infection: similarities and differences. Int J Immunopathol Pharmacol. 2011; 24(3): 673-81[PubMed]
  • 24. Barkhuizen A, Rosen HR, Wolf S, Flora K, Benner K, Bennett RM. Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. Am J Gastroenterol. 1999; 94(5): 1355-60[DOI][PubMed]
  • 25. Hilsabeck RC, Hassanein TI, Perry W. Biopsychosocial predictors of fatigue in chronic hepatitis C. J Psychosom Res. 2005; 58(2): 173-8[DOI][PubMed]
  • 26. Anty R, Marjoux S, Bekri S, DeGalleani L, Dainese R, Gelsi E, et al. Plasma carnitine is associated with fatigue in chronic hepatitis C but not in the irritable bowel syndrome. Aliment Pharmacol Ther. 2011; 33(8): 961-8[DOI][PubMed]
  • 27. El-Gindy EM, Ali-Eldin FA, Meguid MA. Serum leptin level and its association with fatigue in patients with chronic hepatitis C virus infection. Arab J Gastroenterol. 2012; 13(2): 54-7[DOI][PubMed]
  • 28. Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH. Fatigue before, during and after antiviral therapy of chronic hepatitis C: Results from the Virahep-C study. J Hepatol. 2012; 57(5): 946-52[DOI][PubMed]
  • 29. Felger JC, Alagbe O, Pace TW, Woolwine BJ, Hu F, Raison CL, et al. Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue. Brain Behav Immun. 2011; 25(6): 1094-8[DOI][PubMed]
  • 30. Felger JC, Cole SW, Pace TW, Hu F, Woolwine BJ, Doho GH, et al. Molecular signatures of peripheral blood mononuclear cells during chronic interferon-alpha treatment: relationship with depression and fatigue. Psychol Med. 2012; 42(8): 1591-603[DOI][PubMed]
  • 31. Kronenberger B, Berg T, Herrmann E, Hinrichsen H, Gerlach T, Buggisch P, et al. Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. Eur J Gastroenterol Hepatol. 2007; 19(8): 639-46[DOI][PubMed]
  • 32. Malaguarnera M, Vacante M, Bertino G, Neri S, Gargante MP, Motta M, et al. The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-alpha 2b plus ribavirin. J Interferon Cytokine Res. 2011; 31(9): 653-9[DOI][PubMed]
  • 33. Martin KA, Krahn LE, Balan V, Rosati MJ. Modafinil's use in combating interferon-induced fatigue. Dig Dis Sci. 2007; 52(4): 893-6[DOI][PubMed]
  • 34. Rabkin JG, McElhiney MC, Rabkin R. Modafinil and armodafinil treatment for fatigue for HIV-positive patients with and without chronic hepatitis C. Int J STD AIDS. 2011; 22(2): 95-101[DOI][PubMed]
  • 35. Goulding C, O'Connell P, Murray FE. Prevalence of fibromyalgia, anxiety and depression in chronic hepatitis C virus infection: relationship to RT-PCR status and mode of acquisition. Eur J Gastroenterol Hepatol. 2001; 13(5): 507-11[PubMed]
  • 36. Kozanoglu E, Canataroglu A, Abayli B, Colakoglu S, Goncu K. Fibromyalgia syndrome in patients with hepatitis C infection. Rheumatol Int. 2003; 23(5): 248-51[DOI][PubMed]
  • 37. Mohammad A, Carey JJ, Storan E, Scarry M, Coughlan RJ, Lee JM. Prevalence of fibromyalgia among patients with chronic hepatitis C infection: relationship to viral characteristics and quality of life. J Clin Gastroenterol. 2012; 46(5): 407-12[DOI][PubMed]
  • 38. Mohammed RH, ElMakhzangy HI, Gamal A, Mekky F, El Kassas M, Mohammed N, et al. Prevalence of rheumatologic manifestations of chronic hepatitis C virus infection among Egyptians. Clin Rheumatol. 2010; 29(12): 1373-80[DOI][PubMed]
  • 39. Morasco BJ, Huckans M, Loftis JM, Woodhouse J, Seelye A, Turk DC, et al. Predictors of pain intensity and pain functioning in patients with the hepatitis C virus. Gen Hosp Psychiatry. 2010; 32(4): 413-8[DOI][PubMed]
  • 40. Rifai MA, Indest D, Loftis J, Hauser P. Psychiatric management of the hepatitis C patient. Curr Treat Options Gastroenterol. 2006; 9(6): 508-19[PubMed]
  • 41. Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, et al. Hepatitis C infection, antiviral treatment and Mental Health: A European Expert Consensus Statement. J Hepatol. 2012; 57(6): 1379-90[DOI][PubMed]
  • 42. Rifai MA, Gleason OC, Sabouni D. Psychiatric care of the patient with hepatitis C: a review of the literature. Prim Care Companion J Clin Psychiatry. 2010; 12(6)[DOI][PubMed]
  • 43. McMahon JM, Tortu S. A potential hidden source of hepatitis C infection among noninjecting drug users. J Psychoactive Drugs. 2003; 35(4): 455-60[PubMed]
  • 44. el-Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002; 123(2): 476-82[PubMed]
  • 45. Fontana RJ, Hussain KB, Schwartz SM, Moyer CA, Su GL, Lok AS. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol. 2002; 36(3): 401-7[PubMed]
  • 46. Zickmund S, Hillis SL, Barnett MJ, Ippolito L, LaBrecque DR. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology. 2004; 39(4): 999-1007[DOI][PubMed]
  • 47. Gitto S, Micco L, Conti F, Andreone P, Bernardi M. Alcohol and viral hepatitis: a mini-review. Dig Liver Dis. 2009; 41(1): 67-70[DOI][PubMed]
  • 48. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005; 19(2): 105-23[PubMed]
  • 49. Ping F, Shang J, Zhou J, Zhang H, Zhang L. 5-HT(1A) receptor and apoptosis contribute to interferon-alpha-induced "depressive-like" behavior in mice. Neurosci Lett. 2012; 514(2): 173-8[DOI][PubMed]
  • 50. Kenis G, Prickaerts J, van Os J, Koek GH, Robaeys G, Steinbusch HW, et al. Depressive symptoms following interferon-alpha therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor? Int J Neuropsychopharmacol. 2011; 14(2): 247-53[DOI][PubMed]
  • 51. Udina M, Castellvi P, Moreno-Espana J, Navines R, Valdes M, Forns X, et al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry. 2012; 73(8): 1128-38[DOI][PubMed]
  • 52. McNutt MD, Liu S, Manatunga A, Royster EB, Raison CL, Woolwine BJ, et al. Neurobehavioral effects of interferon-alpha in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine. Neuropsychopharmacology. 2012; 37(6): 1444-54[DOI][PubMed]
  • 53. Baraldi S, Hepgul N, Mondelli V, Pariante CM. Symptomatic treatment of interferon-alpha-induced depression in hepatitis C: a systematic review. J Clin Psychopharmacol. 2012; 32(4): 531-43[DOI][PubMed]
  • 54. Kelly EM, Corace K, Emery J, Cooper CL. Bipolar patients can safely and successfully receive interferon-based hepatitis C antiviral treatment. Eur J Gastroenterol Hepatol. 2012; 24(7): 811-6[DOI][PubMed]
  • 55. Sheridan DA, Price DA, Schmid ML, Toms GL, Donaldson P, Neely D, et al. Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin. Aliment Pharmacol Ther. 2009; 29(12): 1282-90[DOI][PubMed]
  • 56. Navines R, Castellvi P, Moreno-Espana J, Gimenez D, Udina M, Canizares S, et al. Depressive and anxiety disorders in chronic hepatitis C patients: reliability and validity of the Patient Health Questionnaire. J Affect Disord. 2012; 138(3): 343-51[DOI][PubMed]
  • 57. Sockalingam S, Abbey SE, Alosaimi F, Novak M. A review of sleep disturbance in hepatitis C. J Clin Gastroenterol. 2010; 44(1): 38-45[DOI][PubMed]
  • 58. Sockalingam S, Shammi C, Stergiopoulos V. Managing the neuropsychiatric complications of hepatitis C treatment. Br J Hosp Med (Lond). 2007; 68(10): 520-5[PubMed]
  • 59. Fletcher NF, McKeating JA. Hepatitis C virus and the brain. J Viral Hepat. 2012; 19(5): 301-6[DOI][PubMed]
  • 60. Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EA, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc. 2003; 9(6): 847-54[DOI][PubMed]
  • 61. Weissenborn K, Krause J, Bokemeyer M, Hecker H, Schuler A, Ennen JC, et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol. 2004; 41(5): 845-51[DOI][PubMed]
  • 62. Huckans M, Seelye A, Woodhouse J, Parcel T, Mull L, Schwartz D, et al. Discounting of delayed rewards and executive dysfunction in individuals infected with hepatitis C. J Clin Exp Neuropsychol. 2011; 33(2): 176-86[DOI][PubMed]
  • 63. Kramer L, Bauer E, Funk G, Hofer H, Jessner W, Steindl-Munda P, et al. Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol. 2002; 37(3): 349-54[PubMed]
  • 64. Perry W, Hilsabeck RC, Hassanein TI. Cognitive dysfunction in chronic hepatitis C: a review. Dig Dis Sci. 2008; 53(2): 307-21[DOI][PubMed]
  • 65. Quarantini LC, Miranda-Scippa A, Batista-Neves S, Powell VB, Abreu N, Abreu KC, et al. A neuropsychological study comparing patients infected with HCV and HBV without psychiatric comorbidities. J Med Virol. 2009; 81(7): 1184-8[DOI][PubMed]
  • 66. Lowry D, Coughlan B, McCarthy O, Crowe J. Investigating health-related quality of life, mood and neuropsychological test performance in a homogeneous cohort of Irish female hepatitis C patients. J Viral Hepat. 2010; 17(5): 352-9[DOI][PubMed]
  • 67. Rodrigue JR, Balistreri W, Haber B, Jonas MM, Mohan P, Molleston JP, et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr. 2009; 48(3): 341-7[DOI][PubMed]
  • 68. Fontana RJ, Bieliauskas LA, Back-Madruga C, Lindsay KL, Litman HJ, Lok AS, et al. Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C. Am J Gastroenterol. 2010; 105(7): 1551-60[DOI][PubMed]
  • 69. Byrnes V, Miller A, Lowry D, Hill E, Weinstein C, Alsop D, et al. Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. J Hepatol. 2012; 56(3): 549-56[DOI][PubMed]
  • 70. Monaco S, Ferrari S, Gajofatto A, Zanusso G, Mariotto S. HCV-Related Nervous System Disorders. Clin Dev Immunol. 2012; 2012: 236148[DOI][PubMed]
  • 71. Pattullo V, McAndrews MP, Damyanovich A, Heathcote EJ. Influence of hepatitis C virus on neurocognitive function in patients free from other risk factors: validation from therapeutic outcomes. Liver Int. 2011; 31(7): 1028-38[DOI][PubMed]
  • 72. Weissenborn K, Ennen JC, Bokemeyer M, Ahl B, Wurster U, Tillmann H, et al. Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut. 2006; 55(11): 1624-30[DOI][PubMed]
  • 73. Martin-Thormeyer EM, Paul RH. Drug abuse and hepatitis C infection as comorbid features of HIV associated neurocognitive disorder: neurocognitive and neuroimaging features. Neuropsychol Rev. 2009; 19(2): 215-31[DOI][PubMed]
  • 74. Crystal H, Kleyman I, Anastos K, Lazar J, Cohen M, Liu C, et al. Effects of hepatitis C and HIV on cognition in women: data from the Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2012; 59(2): 149-54[DOI][PubMed]
  • 75. Blacklaws H, Gardner A, Usher K. Irritability: an underappreciated side effect of interferon treatment for chronic hepatitis C? J Clin Nurs. 2011; 20(9-10): 1215-24[DOI][PubMed]
  • 76. Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG. Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha. Clin Neuropharmacol. 2010; 33(4): 191-7[DOI][PubMed]
  • 77. Bezemer G, Van Gool AR, Fekkes D, Vrolijk JM, Hansen BE, Janssen HL, et al. Psychiatric side effects and fluctuations in serotonergic parameters in the treatment of chronic hepatitis C infection. Neuropsychobiology. 2012; 65(3): 126-32[DOI][PubMed]
  • 78. Butt G. Stigma in the context of hepatitis C: concept analysis. J Adv Nurs. 2008; 62(6): 712-24[DOI][PubMed]
  • 79. Butt G, Paterson BL, McGuinness LK. Living with the stigma of hepatitis C. West J Nurs Res. 2008; 30(2): 204-21[DOI][PubMed]
  • 80. Zickmund S, Ho EY, Masuda M, Ippolito L, LaBrecque DR. "They treated me like a leper". Stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med. 2003; 18(10): 835-44[PubMed]
  • 81. Golden J, Conroy RM, O'Dwyer AM, Golden D, Hardouin JB. Illness-related stigma, mood and adjustment to illness in persons with hepatitis C. Soc Sci Med. 2006; 63(12): 3188-98[DOI][PubMed]
  • 82. Grundy G, Beeching N. Understanding social stigma in women with hepatitis C. Nurs Stand. 2004; 19(4): 35-9[PubMed]
  • 83. Schafer A, Scheurlen M, Felten M, Kraus MR. Physician-patient relationship and disclosure behaviour in chronic hepatitis C in a group of German outpatients. Eur J Gastroenterol Hepatol. 2005; 17(12): 1387-94[PubMed]
  • 84. Moore GA, Hawley DA, Bradley P. Hepatitis C: studying stigma. Gastroenterol Nurs. 2008; 31(5): 346-52[DOI][PubMed]
  • 85. Moore GA, Hawley DA, Bradley P. Hepatitis C: experiencing stigma. Gastroenterol Nurs. 2009; 32(2): 94-104[DOI][PubMed]
  • 86. Kraus MR, Schafer A, Csef H, Scheurlen M, Faller H. Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C. Psychosomatics. 2000; 41(5): 377-84[PubMed]
  • 87. Grassi L, Satriano J, Serra A, Biancosino B, Zotos S, Sighinolfi L, et al. Emotional stress, psychosocial variables and coping associated with hepatitis C virus and human immunodeficiency virus infections in intravenous drug users. Psychother Psychosom. 2002; 71(6): 342-9[PubMed]
  • 88. Sanyal C, Ingram EL, Sketris IS, Peltekian KM, Kirkland S. Coping strategies used by patients infected with hepatitis C virus who are facing medication costs. Can J Hosp Pharm. 2011; 64(2): 131-40[PubMed]
  • 89. Treloar C, Hopwood M. "Look, I'm fit, I'm positive and I'll be all right, thank you very much": coping with hepatitis C treatment and unrealistic optimism. Psychol Health Med. 2008; 13(3): 360-6[DOI][PubMed]
  • 90. Blasiole JA, Shinkunas L, Labrecque DR, Arnold RM, Zickmund SL. Mental and physical symptoms associated with lower social support for patients with hepatitis C. World J Gastroenterol. 2006; 12(29): 4665-72[PubMed]
  • 91. Evon DM, Esserman DA, Ramcharran D, Bonner JE, Fried MW. Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. J Psychosom Res. 2011; 71(5): 349-56[DOI][PubMed]
  • 92. Evon DM, Ramcharran D, Belle SH, Terrault NA, Fontana RJ, Fried MW. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol. 2009; 104(12): 2949-58[DOI][PubMed]
  • 93. Rowan PJ, Al-Jurdi R, Tavakoli-Tabasi S, Kunik ME, Satrom SL, El-Serag HB. Physical and psychosocial contributors to quality of life in veterans with hepatitis C not on antiviral therapy. J Clin Gastroenterol. 2005; 39(8): 731-6[PubMed]
  • 94. Cormier M. The role of hepatitis C support groups. Gastroenterol Nurs. 2005; 28(3 Suppl)-9[PubMed]
  • 95. Edlin BR, Kresina TF, Raymond DB, Carden MR, Gourevitch MN, Rich JD, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis. 2005; 40 Suppl 5-85[DOI][PubMed]
  • 96. Loftis JM, Matthews AM, Hauser P. Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. Drugs. 2006; 66(2): 155-74[PubMed]
  • 97. Khokhar OS, Lewis JH. Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Dig Dis Sci. 2007; 52(5): 1168-76[DOI][PubMed]
  • 98. Hatem C, Minello A, Bresson-Hadni S, Jooste V, Evrard P, Obert B, et al. Is the management of hepatitis C patients appropriate? A population-based study. Aliment Pharmacol Ther. 2005; 21(8): 1007-15[DOI][PubMed]
  • 99. Jecker NS. Caring for "socially undesirable" patients. Camb Q Healthc Ethics. 1996; 5(4): 500-10[PubMed]
  • 100. Lang JP, Michel L, Melin P, Schoeffler M, Gauchet A, Rousseaux C, et al. Management of psychiatric disorders and addictive behaviors in patients with viral hepatitis C in France. Gastroenterol Clin Biol. 2009; 33(1 Pt 1): 1-7[DOI][PubMed]
  • 101. Knott A, Dieperink E, Willenbring ML, Heit S, Durfee JM, Wingert M, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol. 2006; 101(10): 2254-62[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check